Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart drug choice: matching pills to your heart type may beat standard BP care

NCT ID NCT07240909

Disease control Sponsor: The Third Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether choosing blood pressure medication based on a person's specific heart and blood vessel measurements (hemodynamic phenotyping) works better than the usual guideline-based approach. About 240 adults with mild-to-moderate hypertension who have never taken blood pressure drugs will receive either a personalized drug (amlodipine, metoprolol, or indapamide) or standard treatment for 8 weeks. The goal is to see if the personalized method leads to greater blood pressure reduction with similar safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
amlodipine, metoprolol, or indapamide
What this could lead to
If it works, this could show that matching blood pressure drugs to a person's specific heart and blood vessel type leads to better blood pressure control than the usual one-size-fits-all approach.
What could go wrong
This is a relatively small, early-phase trial (240 people) that hasn't started yet. The personalized approach may not prove better than standard care, and results may not apply to everyone with hypertension.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged ≥30 and \<80 years, regardless of gender; 2. Confirmed diagnosis of hypertension meeting the criteria outlined in the 2024 Chinese Hypertension Guidelines: office blood pressure ≥140/90 mmHg and home blood pressure ≥135/85 mmHg; 3. Mild to moderate hypertension, with office blood pressure ranging from 140-179/90-109 mmHg; 4. No prior use of antihypertensive medications; 5. Voluntary participation in the study with written informed consent obtained. Exclusion Criteria: 1. Diagnosed or highly suspected secondary hypertension; 2. Classified as mixed type according to hemodynamic typing; 3. Allergy to the intended antihypertensive medications; 4. Dysphagia; 5. Pregnant or lactating women; 6. Potential pregnancy plans during the trial period; 7. Uncorrected electrolyte disturbances; 8. Severe organ dysfunction; 9. Comorbid conditions leading to inaccurate blood pressure measurement; 10. Comorbid conditions or states unsuitable for noninvasive hemodynamic measurement via bioelectrical impedance; 11. Comorbid conditions contraindicating or requiring caution with trial medications; 12. Comorbid conditions affecting the absorption, distribution, metabolism, or excretion of trial drugs; 13. Concurrent or planned use of medications contraindicated or requiring caution with trial drugs; 14. Concurrent or planned use of medications interfering with trial outcomes; 15. Clinician's assessment deems the patient unsuitable for the trial's antihypertensive regimen; 16. Current participation in other clinical studies that may interfere with the conduct of this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.